Funding announcement: Dr. Lawrence Vernetti has received an SBIR grant in collaboration with Numa Biosciences (formerly Nortis, Inc.) beginning August 1, 2023 for “A liver-on-chip platform to evaluate panels of clinically relevant gene variants for screening of xenobiotic compounds”.